Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group, Clinical Infectious Diseases, vol.34, issue.6, pp.831-837, 2002. ,
DOI : 10.1086/339042
Hepatitis C and Progression of HIV Disease, JAMA, vol.288, issue.2, pp.199-206, 2002. ,
DOI : 10.1001/jama.288.2.199
Correlates of Hepatitis C Virus Infections among Injection Drug Users, Medicine, vol.74, issue.4, pp.212-220, 1995. ,
DOI : 10.1097/00005792-199507000-00005
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France, AIDS, issue.12, pp.171803-1809, 2001. ,
Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus, Clinical Infectious Diseases, vol.33, issue.10, pp.1793-1795, 2001. ,
DOI : 10.1086/323009
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C, Hepatology, vol.49, issue.2, pp.275-279, 2005. ,
DOI : 10.1002/hep.20563
Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.39, issue.4, pp.401-405, 2005. ,
DOI : 10.1097/01.qai.0000170034.90438.68
Pahissa A: Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients, Antivir Ther, issue.8, pp.121217-1223, 2007. ,
Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models, Clinical Pharmacology & Therapeutics, vol.72, issue.4, pp.349-361, 2002. ,
DOI : 10.1067/mcp.2002.127112
Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C, Therapeutic Drug Monitoring, vol.22, issue.5, pp.555-565, 2000. ,
DOI : 10.1097/00007691-200010000-00010
Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C, Antimicrobial Agents and Chemotherapy, vol.47, issue.1, pp.124-129, 2003. ,
DOI : 10.1128/AAC.47.1.124-129.2003
Pharmacokinetics of ribavirin in patients with hepatitis C virus, British Journal of Clinical Pharmacology, vol.43, issue.6, pp.710-714, 2006. ,
DOI : 10.1097/00007691-200212000-00004
Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis, Therapeutic Drug Monitoring, vol.24, issue.6, pp.701-708, 2002. ,
DOI : 10.1097/00007691-200212000-00004
Talal AH: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin, pp.4723-4753, 2007. ,
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C, Hepatology, vol.16, issue.5, pp.471453-1461, 2008. ,
DOI : 10.1002/hep.22217
URL : https://hal.archives-ouvertes.fr/hal-00406823
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.562959-2966 ,
DOI : 10.1128/AAC.05424-11
Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C, Therapeutic Drug Monitoring, vol.31, issue.3, pp.31374-381, 2009. ,
DOI : 10.1097/FTD.0b013e3181a665e3
URL : https://hal.archives-ouvertes.fr/inserm-00369970
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCVco-infected patients treated with ribavirin and pegylated interferon, J Antimicrob Chemother, issue.4, pp.61919-924, 2008. ,
Relative impact of ribavirin monitoring and HIV coinfectiononsustainedvirologicalresponseinpatientswithchronic hepatitis C, Antivir Ther, issue.8, pp.161317-1326, 2011. ,
Therapeutic issues in HIV/HCV-coinfected patients, Journal of Viral Hepatitis, vol.71, issue.3, pp.371-386, 2007. ,
DOI : 10.1053/jhep.2002.36502
Ribavirin in combination therapy for HCV chronic infection in HIV patients: How to win the war after winning the first battle?, Journal of Hepatology, vol.47, issue.1, pp.1-3, 2007. ,
DOI : 10.1016/j.jhep.2007.04.001
Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.292, issue.23, pp.2922839-2848, 2004. ,
DOI : 10.1001/jama.292.23.2839
Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial, AIDS Research and Human Retroviruses, vol.23, issue.8, pp.972-982, 2007. ,
DOI : 10.1089/aid.2007.0011
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection, The Lancet, vol.357, issue.9252, pp.280-281, 2001. ,
DOI : 10.1016/S0140-6736(00)03618-7
High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin, Antivir Ther, vol.9, issue.1, pp.133-138, 2004. ,
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV???HIV International Panel, AIDS, vol.21, issue.9, pp.1073-1089, 2007. ,
DOI : 10.1097/QAD.0b013e3281084e4d